Biolinq has raised $58m in a financing round to support an ongoing pivotal trial investigating its wearable, non-invasive glucose sensor patch. Biolinq’s CEO Richard Yang told Medical Device ...

The most appealing features were long-term sensor life, direct blood glucose measurement and lack of a wearable component ... for glucose monitoring. Biolinq has developed a small, non-invasive ...